Paper41587134
MAGIC: Study Design and Rationale for the Phase 2 Clinical Trial of Faricimab for Non-Proliferative Diabetic Retinopathy.
Zhou AW and 24 others. Ophthalmologica, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. MAGIC: Study Design and Rationale for the Phase 2 Clinical Trial of Faricimab for Non-Proliferative Diabetic Retinopathy. Papers, record 41587134. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41587134
- Disease
- non-proliferative diabetic retinopathy23 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Diabetic Retinopathy | Major topic |
| Fluorescein Angiography | Major topic |
| Visual Acuity | Major topic |
| Retina | Major topic |
| Humans | |
| Prospective Studies | |
| Intravitreal Injections | |
| Tomography, Optical Coherence | |
| Fundus Oculi | |
| Female | |
| Follow-Up Studies | |
| Treatment Outcome | |
| Male | |
| Antibodies, Bispecific |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT05681884 | Safety and Efficacy of Faricimab in Patients With NPDR | Derived from the trial | Yes |
Source ClinicalTrials.gov
References42
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 15215160 | Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. | Am J Pathol | 2004 | https://conductscience.org/library/papers/15215160 | PubMed |
| 2 | 31383483 | Widefield OCT-Angiography and Fluorescein Angiography Assessments of Nonperfusion in Diabetic Retinopathy and Edema Treated with Anti-Vascular Endothelial Growth Factor. | Ophthalmology | 2019 | https://conductscience.org/library/papers/31383483 | PubMed |
| 3 | 26841250 | Contemporary retinal imaging techniques in diabetic retinopathy: a review. | Clin Exp Ophthalmol | 2016 | https://conductscience.org/library/papers/26841250 | PubMed |
| 4 | 32866468 | A critical review: Psychophysical assessments of diabetic retinopathy. | Surv Ophthalmol | 2021 | https://conductscience.org/library/papers/32866468 | PubMed |
| 5 | 26469537 | DETECTION OF MICROVASCULAR CHANGES IN EYES OF PATIENTS WITH DIABETES BUT NOT CLINICAL DIABETIC RETINOPATHY USING OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY. | Retina | 2015 | https://conductscience.org/library/papers/26469537 | PubMed |
| 6 | 27120074 | Evaluating the performance of the quick CSF method in detecting contrast sensitivity function changes. | J Vis | 2016 | https://conductscience.org/library/papers/27120074 | PubMed |
| 7 | 29752001 | Efficacy of Ranibizumab in Eyes with Diabetic Macular Edema and Macular Nonperfusion in RIDE and RISE. | Ophthalmology | 2018 | https://conductscience.org/library/papers/29752001 | PubMed |
| 8 | 26350546 | Diabetic Retinopathy Severity and Peripheral Lesions Are Associated with Nonperfusion on Ultrawide Field Angiography. | Ophthalmology | 2015 | https://conductscience.org/library/papers/26350546 | PubMed |
| 9 | 27472275 | Linking Retinal Microvasculature Features With Severity of Diabetic Retinopathy Using Optical Coherence Tomography Angiography. | Invest Ophthalmol Vis Sci | 2016 | https://conductscience.org/library/papers/27472275 | PubMed |
| 10 | 29545417 | Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe in 2015: magnitude, temporal trends and projections. | Br J Ophthalmol | 2018 | https://conductscience.org/library/papers/29545417 | PubMed |
| 11 | 22402896 | Vision, retinal thickness, and foveal avascular zone size after intravitreal bevacizumab for diabetic macular edema. | Adv Ther | 2012 | https://conductscience.org/library/papers/22402896 | PubMed |
| 12 | 36749332 | Four-Year Visual Outcomes in the Protocol W Randomized Trial of Intravitreous Aflibercept for Prevention of Vision-Threatening Complications of Diabetic Retinopathy. | JAMA | 2023 | https://conductscience.org/library/papers/36749332 | PubMed |
| 13 | 23355773 | Changes in the foveal microstructure after intravitreal bevacizumab application in patients with retinal vascular disease. | Clin Ophthalmol | 2013 | https://conductscience.org/library/papers/23355773 | PubMed |
| 14 | 38881606 | Visual Function Measurements in Eyes With Diabetic Retinopathy: An Expert Opinion on Available Measures. | Ophthalmol Sci | 2024 | https://conductscience.org/library/papers/38881606 | PubMed |
| 15 | 27847598 | A review of optical coherence tomography angiography (OCTA). | Int J Retina Vitreous | 2015 | https://conductscience.org/library/papers/27847598 | PubMed |
| 16 | 35257962 | Final Outcomes from the Randomized RECOVERY Trial of Aflibercept for Retinal Nonperfusion in Proliferative Diabetic Retinopathy. | Ophthalmol Retina | 2022 | https://conductscience.org/library/papers/35257962 | PubMed |
| 17 | 35980610 | Association of Ultra-Widefield Fluorescein Angiography-Identified Retinal Nonperfusion and the Risk of Diabetic Retinopathy Worsening Over Time. | JAMA Ophthalmol | 2022 | https://conductscience.org/library/papers/35980610 | PubMed |
| 18 | 23706926 | Contrast sensitivity basics and a critique of currently available tests. | J Cataract Refract Surg | 2013 | https://conductscience.org/library/papers/23706926 | PubMed |
| 19 | 17166891 | Clinical assessment of two new contrast sensitivity charts. | Br J Ophthalmol | 2007 | https://conductscience.org/library/papers/17166891 | PubMed |
| 20 | 35017700 | Retinal non-perfusion in diabetic retinopathy. | Eye (Lond) | 2022 | https://conductscience.org/library/papers/35017700 | PubMed |
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| FARICIMAB | CHEMBL4297750 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL4297750 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- Cited by
- Genes
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41587134
GET https://conductscience.org/api/papers/v1/41587134/authors?page=2